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Machine learning prediction 
for mortality of patients diagnosed 
with COVID‑19: a nationwide 
Korean cohort study
Chansik An1, Hyunsun Lim1, Dong‑Wook Kim2, Jung Hyun Chang1,3, Yoon Jung Choi1,4* & 
Seong Woo Kim5
The rapid spread of COVID‑19 has resulted in the shortage of medical resources, which necessitates 
accurate prognosis prediction to triage patients effectively. This study used the nationwide cohort of 
South Korea to develop a machine learning model to predict prognosis based on sociodemographic 
and medical information. Of 10,237 COVID‑19 patients, 228 (2.2%) died, 7772 (75.9%) recovered, 
and 2237 (21.9%) were still in isolation or being treated at the last follow‑up (April 16, 2020). The 
Cox proportional hazards regression analysis revealed that age > 70, male sex, moderate or severe 
disability, the presence of symptoms, nursing home residence, and comorbidities of diabetes mellitus 
(DM), chronic lung disease, or asthma were significantly associated with increased risk of mortality 
(p ≤ 0.047). For machine learning, the least absolute shrinkage and selection operator (LASSO), 
linear support vector machine (SVM), SVM with radial basis function kernel, random forest (RF), and 
k‑nearest neighbors were tested. In prediction of mortality, LASSO and linear SVM demonstrated 
high sensitivities (90.7% [95% confidence interval: 83.3, 97.3] and 92.0% [85.9, 98.1], respectively) 
and specificities (91.4% [90.3, 92.5] and 91.8%, [90.7, 92.9], respectively) while maintaining high 
specificities > 90%, as well as high area under the receiver operating characteristics curves (0.963 
[0.946, 0.979] and 0.962 [0.945, 0.979], respectively). The most significant predictors for LASSO 
included old age and preexisting DM or cancer; for RF they were old age, infection route (cluster 
infection or infection from personal contact), and underlying hypertension. The proposed prediction 
model may be helpful for the quick triage of patients without having to wait for the results of 
additional tests such as laboratory or radiologic studies, during a pandemic when limited medical 
resources must be wisely allocated without hesitation.
A pneumonia of unknown cause detected in Wuhan, China was first reported to the World Health Organiza-
tion (WHO) on December 31, 2019. A few weeks later, it was found to be caused by a novel  coronavirus1. On 
February 11, 2020, the WHO formally named the causative coronavirus the severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) and the disease caused by the virus, the coronavirus disease 2019 (COVID-19). 
COVID-19 is the third known zoonotic coronavirus disease after SARS and the Middle East Respiratory Syn-
drome (MERS)2. After the onset of its rapid spread worldwide, the WHO declared the COVID-19 outbreak a 
global pandemic on March 11, 2020.
COVID-19 has a higher mortality rate (3.8% according to the WHO as of August 2020) than influenza and 
spreads more rapidly over much wider areas than prior coronavirus diseases. COVID-19 has already claimed 
far more lives than its predecessors (813 deaths for SARS and 858 deaths for MERS)3,4. As of October 05, 2020, 
COVID-19 had infected over 35 million people with the worldwide death toll exceeding 1,040,0005.
Because of the rapid spread of the virus, there has been a sharp increase in the demand for medical resources 
required to support infected people. Despite the desperate efforts to contain the disease and slow down its spread, 
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many countries have been suffering from the shortage of hospital beds and critical care equipment for the timely 
treatment of ill  patients6–8. Therefore, in addition to efficient diagnosis and treatment, accurate prognosis predic-
tion is necessary to reduce the strain on healthcare systems and provide the best possible care for patients. When 
allocating limited medical resources, prediction models that estimate the risk of a poor outcome in an infected 
individual based on pre-diagnosis information could help to effectively triage patients.
All Koreans are mandated to enroll in national health insurance, except for the population in the lowest 
income bracket, who is funded by taxes and covered by Medicaid. Consequently, information regarding the 
sociodemographic characteristics and history of medical service use of virtually all Koreans is available in the 
database where currently information regarding COVID-19 patients is also periodically updated.
The purpose of this study was to develop and validate machine learning models that predict the prognosis of 
COVID-19 patients based on sociodemographic information, infection route, and medical status and history, 
for the nationwide cohort of South Korea.
Results
Baseline characteristics. The patient characteristics are summarized in Table 1. The mean (± standard 
deviation [SD]) age was 44.97 (± 19.79) years; patients who died of COVID-19 were significantly older than 
those who recovered, with the mean (± SD) age being 78.17 (± 10.96) years and 43.06 (± 18.32) years, respec-
tively. Women comprised 60.1% of the study population. Approximately 38.5% of the patients were symptomatic 
at the time of diagnosis. A majority of the infections (58.1%) were cluster infection, and 11.3% of the patients 
were nursing home residents. Of the 10,237 patients, 3147 (30.7%) had one or more underlying medical con-
ditions; the four most common conditions were hypertension (18.2%), hyperlipidemia (18.0%), chronic lung 
disease or asthma (10.5%), and diabetes mellitus (DM) (10.0%).
Mortality from COVID‑19. A total of 10,237 patients were diagnosed with COVID-19 between January 
23, 2020 and April 2, 2020 and were followed up until April 16, 2020. The case fatality ratio was 2.85% (228 
deaths and 7772 recoveries). The median interval between diagnosis and mortality was 9 days (range 0–49 days), 
and 22 days (range 0–75 days) between diagnosis and recovery (Fig. 1). No significant difference in the interval 
between diagnosis and mortality or recovery was found among different age groups (p > 0.231) (Fig. 2).
Factors associated with mortality. Cox proportional hazards model. In the multivariable analysis with 
medication excluded (Table 2), age > 70, male sex, moderate or severe disability, the presence of symptoms, infec-
tion at a nursing home, DM, and chronic lung disease or asthma were significantly associated with increased risk 
of mortality (p ≤ 0.047), whereas age < 40 and cluster infection or infection from personal contact or visit were as-
sociated with decreased risk (p ≤ 0.007). In the multivariable analysis with underlying disease excluded (Table 3), 
the use of loop diuretics or acarbose was significantly associated with increased risk of mortality (p ≤ 0.018).
Variable importance from machine learning. In predicting the final outcome (i.e., mortality vs. recovery), the 
five most significant predictors for the least absolute shrinkage and selection operator (LASSO) were age > 80, 
taking of acarbose, age > 70, taking of metformin, and underlying cancer in order of significance; for random 
forest (RF) they were cluster infection, infection from personal contact or visit, underlying hypertension, and 
age > 80 (Fig. 3). In predicting early mortality, similar patterns were observed (Supplementary Figs. 1 and 2). 
Overall, in addition to old age, LASSO focused on DM medication and cancer whereas RF relied on the infection 
route and hypertension.
Performance of machine learning. The performances of the machine learning models in the final test-
ing are summarized in Table 4. The optimized hyperparameters can be found in Supplementary Table 1. LASSO 
and linear support vector machine (SVM) showed high areas under the receiver operating characteristic curves 
(AUCs) (> 0.9), high balanced accuracies (> 91% for final mortality and > 86% for 14- or 30-day mortality), and 
sensitivities (> 90% for final mortality and > 83% for 14- or 30-day mortality) without compromising specifici-
ties (approximately 90%). However, the sensitivities of RF and radial basis function (RBF)-SVM were < 50%, 
ranging between 10.2% and 42.7% despite their high AUCs and specificities. K-nearest neighbor (KNN) showed 
the lowest AUCs and intermediate sensitivities and balanced accuracies. Regardless of the machine learning 
model, negative predictive values (NPVs) were high (> 97%), and positive predictive values (PPVs) were low 
(13.0–44.4%). All the models displayed have higher performances in long-term prediction than in short-term 
prediction.
Discussion
Our results demonstrate that machine learning models utilizing sociodemographic characteristics and medical 
history can accurately predict the prognosis of COVID-19 patients after diagnosis; the models predict not only 
the final outcome (i.e., mortality vs. recovery) but also early mortality (i.e., 14- or 30-day mortality). The pro-
posed prediction model aims at the quick triage of patients without having to wait for the results of additional 
tests such as laboratory or radiologic studies, during a pandemic when limited medical resources must be wisely 
allocated without hesitation.
Machine learning is focused on achieving high predictive accuracy without much focus on explaining how 
the accuracy is achieved. We presented the result of the Cox proportional hazard regression and variable impor-
tance as complements, showing how importantly input variables were used by LASSO and RF. In line with 
previous  studies9–20, old age, male gender, and the presence of symptoms or underlying medical conditions 
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Mortality (N = 228)
Survived




 < 40 1 (0.4%) 3520 (45.3%) 907 (40.5%) 4428 (43.3%)
40–50 3 (1.3%) 1093 (14.1%) 231 (10.3%) 1327 (13.0%)
50–60 12 (5.3%) 1529 (19.7%) 338 (15.1%) 1879 (18.4%)
60–70 30 (13.2%) 1023 (13.2%) 332 (14.8%) 1385 (13.5%)
70–80 65 (28.5%) 429 (5.5%) 204 (9.1%) 698 (6.8%)
 > 80 117 (51.3%) 178(2.3%) 225(10.1%) 520 (5.1%)
Sex
Female 121 (53.1%) 4790 (61.6%) 1252 (56.0%) 6149 (60.1%)
Male 107 (46.9%) 2982 (38.4%) 985 (44.0%) 4088 (39.9%)
Income level†
Medicaid 42 (18.4%) 569 (7.3%) 260 (11.6%) 871 (8.5%)
 < 25% 39 (17.1%) 2000 (25.7%) 453 (20.3%) 2492 (24.3%)
25–50% 29 (12.7%) 1437 (18.5%) 334 (14.9%) 1800 (17.6%)
50–75% 35 (15.4%) 1675 (21.6%) 436 (19.5%) 2146 (21.0%)
 > 75% 82 (36.0%) 2032 (26.1%) 747 (33.4%) 2861 (27.9%)
Residence
Suburban/rural 2 (0.9%) 240 (3.1%) 419 (18.7%) 661 (6.5%)
Urban 149 (65.4%) 5657 (72.8%) 1018 (45.5%) 6824 (66.7%)
Metropolitan 77 (33.8%) 1875 (24.1%) 800 (35.8%) 2752 (26.9%)
Household type
Others 161 (70.6%) 7503 (96.5%) 2044 (91.4%) 9708 (94.8%)
Seniors (> 65 y) living 
alone 67 (29.4%) 269 (3.5%) 193 (8.6%) 529 (5.2%)
Disability
None 166 (72.8%) 7352 (94.6%) 1959 (87.6%) 9477 (92.6%)
Mild 40 (17.5%) 301 (3.9%) 175 (7.8%) 516 (5.0%)
Moderate or severe 22 (9.6%) 119 (1.5%) 103 (4.6%) 244 (2.4%)
Symptom
Absent 133 (58.3%) 4370 (56.2%) 1791 (80.1%) 6294 (61.5%)
Present 95 (41.7%) 3402 (43.8%) 446 (19.9%) 3943 (38.5%)
Infection route
Personal contact 16 (7.0%) 1043 (13.4%) 250 (11.2%) 1309 (12.8%)
Cluster infection 26 (11.4%) 5379 (69.2%) 542 (24.2%) 5947 (58.1%)
Nursing home 127 (55.7%) 443 (5.7%) 584 (26.1%) 1154 (11.3%)
From abroad 0 (0.0%) 188 (2.4%) 710 (31.7%) 898 (8.8%)
Unclassified 59 (25.9%) 719 (9.3%) 151 (6.8%) 929 (9.1%)
Underlying medical 
condition‡
None 26 (11.4%) 5733 (73.8%) 1331 (59.5%) 7090 (69.3%)
Hypertension 165 (72.4%) 1154 (14.8%) 545 (24.4%) 1864 (18.2%)
Diabetes mellitus 107 (46.9%) 580 (7.5%) 334 (14.9%) 1021 (10.0%)
Hyperlipidemia 112 (49.1%) 1252 (16.1%) 479 (21.4%) 1843 (18.0%)
Cardiovascular disease 70 (30.7%) 280 (3.6%) 161 (7.2%) 511 (5.0%)
Cerebrovascular disease 4 (1.8%) 5 (0.1%) 18 (0.8%) 27 (0.3%)
Cancer 9 (3.9%) 40 (0.5%) 27 (1.2%) 76 (0.7%)
Chronic lung disease or 
Asthma 93 (40.8%) 730 (9.4%) 257 (11.5%) 1080 (10.5%)
Chronic renal disease 13 (5.7%) 42 (0.5%) 23 (1.0%) 78 (0.8%)
Mental illness 58 (25.4%) 126 (1.6%) 313 (14.0%) 497 (4.9%)
Chronic liver disease 10 (4.4%) 157 (2.0%) 64 (2.9%) 231 (2.3%)
Medication‡
ACE inhibitor 5 (2.2%) 30 (0.4%) 13 (0.6%) 48 (0.5%)
AR blocker 62 (27.2%) 636 (8.2%) 224(10.0%) 922 (9.0%)
Beta blocker 29 (12.7%) 189 (2.4%) 89 (4.0%) 307 (3.0%)
Calcium channel blocker 59 (25.9%) 529 (6.8%) 209 (9.3%) 797 (7.8%)
Loop diuretics 14 (6.1%) 21 (0.3%) 21 (0.9%) 56 (0.5%)
Acarbose 2 (0.9%) 3 (0.0%) 2 (0.1%) 7 (0.1%)
Sulfonylurea 22 (9.6%) 125 (1.6%) 65 (2.9%) 212 (2.1%)
Metformin 45 (19.7%) 261 (3.4%) 117 (5.2%) 423 (4.1%)
DDP-4 26 (11.4%) 141 (1.8%) 62 (2.8%) 229 (2.2%)
Fenofibrate 4 (1.8%) 44 (0.6%) 15 (0.7%) 63 (0.6%)
Statin 69 (30.3%) 742 (9.5%) 263 (11.8%) 1074 (10.5%)
NSAID 12 (5.3%) 64 (0.8%) 29 (1.3%) 105 (1.0%)
Aspirin 57 (25.0%) 305 (3.9%) 136 (6.1%) 498 (4.9%)
Table 1.  Baseline characteristics. Recovered or undetermined cases were censored at the date of recovery or 
the date of last follow-up (April 16, 2020), respectively. ACE angiotensin-converting enzyme, AR angiotensin 
receptor, NSAID non- steroidal anti-inflammatory drug. *In isolation or under treatment. † 67 patients with 
missing values were excluded. ‡ Some patients had more than one medical condition or medication.
4
Vol:.(1234567890)
Scientific Reports |        (2020) 10:18716  | https://doi.org/10.1038/s41598-020-75767-2
www.nature.com/scientificreports/
were significantly associated with worse prognosis. We additionally found that moderate or severe disability and 
infection route were independently associated with prognosis.
Almost all previous studies reported that old age was a strong prognostic factor, and this was also confirmed 
by our results. However, the time to recovery or mortality did not differ by age in our study population.
Previously reported underlying medical conditions associated with poor prognosis include 
 hypertension10,12,13,15,17,18,  DM10,12,14,15, lung disease including chronic obstructive lung disease and  asthma11–13, 
cardiovascular  disease10,11,13–15,  cancer21,22, and chronic renal  disease12,18. In our study, DM (from Cox and 
LASSO), chronic lung disease or asthma (from Cox regression), cancer (from LASSO), and hypertension (from 
RF) were significant predictors. LASSO paid more attention to DM medication than the disease itself, which may 
have been because patients taking medication were more likely to have had DM longer than those not taking 
it. The insignificance of the other medical conditions, such as cardiovascular disease or chronic renal disease in 
our study, may be due to a different study population, the broadness of our operational definition of the diseases, 
and correlation with other strong predictive factors.
Figure 1.  Histogram illustrating the distribution of the time interval between diagnosis and recovery (A) or 
mortality (B).
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We also performed multivariable Cox regression to identify drugs associated with increased or decreased risk 
of mortality and found that the use of loop diuretics or acarbose was an independent risk factor. However, these 
results need to be interpreted cautiously. There may have been other confounding factors among the patients 
who consume this medication that we were unable to sufficiently adjust for. Loop diuretics are recommended to 
be considered in patients with congestive heart failure or advanced chronic renal  disease23. Alpha-glucosidase 
inhibitors including acarbose are often used with a basal insulin regimen when basal insulin treatment alone 
did not result in glycemic control, especially postprandial glucose level in  Asians24. Thus, the poor outcome in 
the patients taking the medications may have been due to the fact that they had have a longer duration of more 
comorbidities, not due to the direct drug effects.
Our main interest for the medication analysis was the angiotensin converting enzyme (ACE) inhibitors and 
angiotensin receptor (AR) blockers. There have been concerns regarding a potential harmful effect caused by 
ACE inhibitors and AR blockers in COVID-19  patients25. In our study, however, the use of ACE inhibitors or 
AR blockers was not significantly associated with mortality from COVID-19, in agreement with a recent large-
scale  study11.
Recent discussions pointed out the potential beneficial or harmful effects of other commonly prescribed drugs 
including antidiabetic drugs, statin, and aspirin in patients with COVID-1926–30. Some evidence suggested that 
Table 2.  Results of Cox proportional hazards regression without medication. HR hazard ratio, CI confidence 
interval; 0651.
Univariable Multivariable
HR (95% CI) p-value HR (95% CI) p-value
Age (years)
 < 40 0.04 (0.01, 0.28) 0.001 0.06 (0.01, 0.46) 0.007
40–50 0.35 (0.10, 1.25) 0.107 0.47 (0.13, 1.68) 0.246
50–60 Reference
60–70 3.12 (1.58, 6.17) 0.001 1.97 (0.99, 3.93) 0.054
70–80 13.49 (7.23, 25.17)  < .0001 7.31 (3.77, 14.16)  < .0001
 > 80 40.49 (22.30, 73.50)  < .0001 17.46 (9.01, 33.85)  < .0001
Sex
Female Reference
Male 1.86 (1.42, 2.44)  < .0001 2.37 (1.78, 3.15)  < .0001
Income level
Medicaid 3.35 (2.12, 5.29)  < .0001 1.34 (0.82, 2.19) 0.250
 < 25% Reference
25–50% 1.07 (0.65, 1.77) 0.781 1.35 (0.81, 2.26) 0.247
50–75% 1.18 (0.74, 1.88) 0.492 1.15 (0.71, 1.85) 0.566
 > 75% 1.89 (1.26, 2.83) 0.002 1.05 (0.69, 1.60) 0.814
Residence
Suburban/rural Reference
Urban 0.72 (0.54, 0.96) 0.023 1.29 (0.94, 1.77) 0.119
Metropolitan 0.13 (0.03, 0.53) 0.004 0.82 (0.20, 3.40) 0.784
Household type
Others reference
Seniors (> 65 y) living alone 8.33 (6.21, 11.2)  < .0001 1.06 (0.76, 1.48) 0.717
Disability
None Reference
Mild 4.76 (3.32, 6.82)  < .0001 0.98 (0.67, 1.42) 0.911
Moderate or severe 6.19 (3.96, 9.68)  < .0001 1.63 (1.01, 2.63) 0.047
Symptom
Absent reference
Present 1.08 (0.82, 1.42) 0.591 2.29 (1.70, 3.09)  < .0001
Infection route
Unclassified Reference
Large clusters 0.08 (0.05, 0.12)  < .0001 0.31 (0.19, 0.52)  < .0001
Nursing home 2.42 (1.73, 3.38)  < .0001 1.68 (1.10, 2.56) 0.017
Personal contact 0.22 (0.12, 0.39)  < .0001 0.24 (0.13, 0.43)  < .0001
Underlying medical condition
None Reference
Hypertension 12.18 (9.02, 16.46)  < .0001 1.22 (0.87, 1.73) 0.254
Diabetes mellitus 8.30 (6.33, 10.89)  < .0001 1.75 (1.29, 2.36) 0.001
Hyperlipidemia 4.27 (3.26, 5.60 )  < .0001 0.89 (0.66, 1.20) 0.446
Cardiovascular disease 8.48 (6.29, 11.42)  < .0001 1.23 (0.89, 1.70) 0.220
Cerebrovascular disease 8.53 (3.17, 22.96)  < .0001 0.88 (0.32, 2.44) 0.801
Cancer 5.06 (2.38, 10.75)  < .0001 1.64 (0.75, 3.60) 0.216
Chronic lung disease or Asthma 5.54 (4.20, 7.31)  < .0001 1.83 (1.37, 2.46)  < .0001
Chronic renal disease 9.37 (5.35, 16.43)  < .0001 1.47 (0.80, 2.69) 0.215
Mental illness 8.49 (6.22, 11.57)  < .0001 1.01 (0.69, 1.49) 0.948
Chronic liver disease 1.74 (0.86, 3.52) 0.126 0.76 (0.37, 1.57) 0.462
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the use of DDP-4, metformin, and statin may be associated with better prognosis in COVID-19  patients27,30,31. 
However, none of these effects has been validated yet. Due to the data structure and study design, we were also 
unable to effectively investigate the independent effects of such drugs. A further investigation is warranted, and 
several clinical studies including NCT04467931, NCT04510194, NCT04365309, and NCT04407273, are being 
planned or conducted to examine the potential association of the drugs with prognosis in COVID-19  patients32.
Our data had information regarding infection route, which showed that patients at nursing homes had worse 
prognosis whereas those who contracted the disease from large clusters had better outcomes. This may be attrib-
uted to the age distribution and the status of underlying diseases in these groups; most nursing home residents 
are elderly people with underlying diseases, whereas the infection clusters in Korea during the current outbreak 
were mostly churches and service call centers where a majority of attendees were young.
We tested several machine learning algorithms because the most appropriate algorithm may differ depending 
on data structure and a given task. LASSO and linear SVM demonstrated high sensitivities (> 90%) and almost 
perfect NPV (99.7%) in predicting mortality, which is clinically important because identifying and detecting 
at-risk patients is more significant than reducing false positive prediction. However, the other models showed 
low sensitivities despite our efforts to compensate for the class imbalance by up-sampling rare mortality cases 
and adding class weights when training them. Although we were not able to fully understand and explain this 
failure to overcome the class imbalance in these models, the difference in variable importance by LASSO and 
RF may be helpful in explaining the results. The two most important predictors for RF were cluster infection 
and personal contact where a very small proportion of the patients (0.6%, 42/7256) died, implying that RF chose 
to focus on detecting negative cases to achieve high AUC. In contrast, LASSO appears to have focused on the 
predictors associated with increased risk of mortality including old age and DM.
The current study has limitations. First, the data used in this study did not have information regarding labo-
ratory or radiologic results which may also be important prognostic  factors10,17–19,33. However, our prediction 
model aims at early prognosis prediction at the time of diagnosis before further diagnostic studies or treatment. 
Second, the treatments of patients can have a large impact on prognosis; however, we assumed that our patients 
all had standard therapy. In Korea, all patients are sent to designated hospitals with medical staff and equipment 
required to provide prompt standard therapy, and this is attributed to aggressive diagnosis and early intervention.
In conclusion, we have developed and validated robust machine learning models, which could be used to pre-
dict the prognosis of COVID-19 patients. LASSO and linear SVM demonstrated high sensitivities and specificities 
for identifying at-risk patients. Age, sex, moderate or severe disability, the presence of symptoms, and comor-
bidities including hypertension, DM, chronic lung disease or asthma, and cancer were significant risk factors.
Materials and methods
The Institutional Review Board of National Health Insurance Service Ilsan Hospital (NHIMC 2020-04-026) 
approved this retrospective Health Insurance Portability and Accountability Act-compliant cohort study and 
waived the informed consent from the participants, because this study was expected to present no or minimal 
risk of harm to the participants, and all the data used were anonymized. All methods were performed in accord-
ance with relevant guidelines and regulations.
Data source. This study used a merged dataset combining relevant information from two data sources pro-
vided by the Korean National Health Insurance Service (KNHIS): the database of beneficiaries of national health 
insurance and the newly added database of patients with confirmed diagnosis of COVID-19. The KNHIS data-
Table 3.  Results of Cox proportional hazards regression for medication. *Adjusted for age, sex, income level, 
residence, household type, disability, symptom, and infection route. HR hazard ratio, CI confidence interval, 
ACE angiotensin-converting enzyme, AR angiotensin receptor, DDP-4 dipeptidyl peptidase-4, NSAID non- 
steroidal anti-inflammatory drug.
Univariable Multivariable*
HR (95% CI) p-value HR (95% CI) p-value
ACE inhibitor 4.30 (1.60, 11.56) 0.004 0.58 (0.20, 1.68) 0.314
AR blocker 3.58 (2.63, 4.87)  < .0001 0.93 (0.65, 1.32) 0.668
Beta blocker 4.77 (3.16, 7.19)  < .0001 1.18 (0.73, 1.88) 0.502
Calcium channel blocker 3.81 (2.77, 5.24)  < .0001 1.03 (0.72, 1.48) 0.875
Loop diuretics 14.64 (8.35, 25.67)  < .0001 2.17 (1.14, 4.11) 0.018
Acarbose 15.45 (3.84, 62.20) 0.001 8.36 (1.89, 36.93) 0.005
Sulfonylurea 5.43 (3.46, 8.53)  < .0001 1.12 (0.66, 1.93) 0.671
Metformin 5.82 (4.13, 8.18)  < .0001 1.41 (0.86, 2.33) 0.179
DDP-4 inhibitor 5.84 (3.82, 8.93)  < .0001 1.29 (0.75, 2.21) 0.358
Fenofibrate 3.47 (2.57, 4.68)  < .0001 0.87 (0.59, 1.28) 0.470
Statin 3.23 (1.20, 8.68) 0.020 1.23 (0.44, 3.44) 0.688
NSAID 5.11 (2.71, 9.65)  < .0001 1.31 (0.68, 2.53) 0.424
Aspirin 6.58 (4.80, 9.02)  < .0001 1.19 (0.79, 1.79) 0.397
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base provides all information regarding reimbursement for outpatient visits and hospital admissions, includ-
ing sociodemographic information, medical diagnoses, procedures, prescriptions, and national health check-up 
results. Because virtually all Koreans are covered by national health insurance or Medicaid, the abovementioned 
information was available for all of our study participants. Detailed information on the KNHIS database includ-
ing data configuration has been outlined  elsewhere34,35. Data cannot be shared publicly because of the provisions 
of the KNHIS which prohibit authors from making the data publicly available and provides a limited portion of 
anonymized data to researchers for the purpose of a public interest.
Patients. The study included 10,237 Korean patients who had tested positive for COVID-19 from Jan 23, 
2020 to Apr 16, 2020 (Fig. 4). Of these patients, 228 (2.2%) had died, 7772 (75.9%) had recovered, and 2237 
(21.9%) were still in isolation or being treated. Sixty-seven patients lacked information on their income statuses 
and were excluded for cox proportional hazard regression and estimation of variable importance by machine 
learning.
The sociodemographic and medical information included as potential predictive factors were age, sex, income 
level, place of residence, household type, disability, respiratory symptoms, infection route, underlying medical 
conditions, and medication (Table 1). The income level was divided into five categories; people in the lowest 
level were covered by Medicaid, and the four upper levels included quartiles of the insured patients based on the 
amount of their monthly contributions. Household type had two categories: seniors (> 65 year) living alone and 
other house types. There were five categories of infection route: personal contact with an infected person or visit 
to an affected area, cluster infection (e.g., from a religious gathering or packed workplace), infection at a nursing 
home, infection from abroad, and unclassified. In the KNHIS database, diagnoses were coded according to the 
Korean Standard Classification of Diseases (KCD) version 6, which is based on the International Classification 
of Diseases 10th revision (ICD-10). The operational definitions of the medical conditions used in this study are 
presented in Supplementary Table 2. Based on the prescription information provided by the KNHIS, patients 
were considered to be on medication if they had received a prescription that lasted more than 180 days for the 
Table 4.  Final performance of machine learning models in prediction of mortality from COVID-19 in the test 
set. Values in parentheses are 95% confidence intervals. AUC area under the receiver operating characteristic 
curve, TP true positive, FP false positive, FN false negative, TN true negative, PPV positive predictive value, 
NPV negative predictive value, LASSO least absolute shrinkage and selection operator, SVM support vector 
machine, RBF radial basis function kernel, RF random forest, KNN k-nearest neighbors.
Classifier AUC TP/FP/FN/TN Sensitivity Specificity PPV NPV
Balanced 
accuracy
Mortality vs. recovery (with undetermined cases excluded)






















RBF-SVM 0.958 (0.945, 0.971) 32/53/43/2372
42.7% (31.5, 





























Mortality vs. survival within 14 days after diagnosis





















































Mortality vs. survival within 30 days after diagnosis
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last year. Medications reported to be potentially associated with COVID-19 prognosis were examined in this 
 study11,26,30,36,37: various types of antihypertensive drugs (ACE inhibitors, AR blockers, beta-blockers, calcium 
channel blockers and loop diuretics), antidiabetic drugs (acarbose, sufonylurea, metformin, and DDP-4), and 
lipid-lowering drugs (statin and fenofibrate), non-steroidal anti-inflammatory drug, and aspirin.
Statistical analysis. The Kruskal–Wallis test was performed to compare the age groups. The Cox propor-
tional hazards model was used to assess the hazard ratios of mortality from COVID-19. Following univariable 
analyses, multivariable analyses were performed to identify independent predictive factors, first with medication 
usage excluded, and then with underlying disease excluded. This is because the existence of underlying diseases 
and medication usage are expected to have strong correlations with mortality from COVID-19. Recovered or 
undetermined cases were censored at the date of recovery or the date of last follow-up (April 16, 2020), respec-
tively. Two-sided probability values of < 0.05 were considered statistically significant. The statistical analyses 
were performed using the SAS software (version 9.4.3.0; SAS Institute, Cary NC, USA).
Machine learning. The dataset was randomly split into training and test sets in a ratio of 7:3 while preserv-
ing the same proportion of mortality in both sets. Because only a small proportion (2.2%) of the study popula-
tion died of COVID-19, using accuracy as an evaluation metric is inappropriate. In our study population, an 
accuracy of 97.8% could be achieved simply by predicting no death every time, which would be a useless classi-
fier as it would result in zero sensitivity. To mitigate the issue of imbalanced classes, we oversampled rare cases, 
performed class weighting, and used an evaluation metric of AUC that is more appropriate for data with imbal-
anced classes than accuracy, when fitting our model in the training set.
The machine learning algorithms used in this study were LASSO, linear SVM, RBF-SVM, RF, and KNN. 
Including irrelevant features in a machine learning model likely results in overfitting and can undermines the 
generalizability of a prediction  model38. Thus, LASSO and SVM were regularized using L1-norm which auto-
matically selects important  features39. For RF, k most important features were selected based on the variable 
importance, with k being a hyperparameter that is optimized through cross validation. For KNN, only the features 
that had been independently associated with mortality in the multivariable Cox regression were used as input 
data. After the feature selection, the algorithms were trained and tested for classifying mortality vs. recovery 
after excluding 2237 undetermined cases (i.e., patients who were not cured nor died, but were still in isolation 
or being treated at the last follow-up). Subsequently, we developed models to predict 14- or 30-day mortality, for 
which the study population was divided into two groups: patients who died of COVID-19 vs. those who did not 
within 14 days or 30 days after diagnosis, respectively. Hyperparameter optimization was performed through 
Figure 4.  Flow diagram for study participants.
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tenfold cross validation using grid search in the training set. After each optimal model was found, it was fit in 
the entire training set and tested in the test set.
Using LASSO and RF, the importance of all variables were evaluated and scaled to have a maximum value of 
100. Information regarding variable importance was not obtainable from SVM or KNN. Machine learning was 
performed using the R software (version 3.4.4, R Foundation for Statistical Computing, Vienna, Austria) with 
the caret package (version 6.0-86).
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